Viridian Therapeutics Inc’s recent filing unveils that its Director Fairmount Funds Management LLC acquired Company’s shares for reported $10.0 million on Oct 23 ’25. In the deal valued at $22.00 per share,454,545 shares were bought. As a result of this transaction, Fairmount Funds Management LLC now holds 3,914,458 shares worth roughly $126.48 million.
Wedbush reiterated its Viridian Therapeutics Inc [VRDN] rating to an Outperform in a research note published on December 10, 2025; the price target was $47. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. Truist began covering VRDN with “Buy” recommendation on November 24, 2025.
Price Performance Review of VRDN
On Friday, Viridian Therapeutics Inc [NASDAQ:VRDN] saw its stock fall -0.80% to $32.31. Over the last five days, the stock has gained 0.91%. Viridian Therapeutics Inc shares have risen nearly 66.89% since the year began. Nevertheless, the stocks have risen 68.54% over the past one year. While a 52-week high of $33.34 was reached on 12/04/25, a 52-week low of $9.90 was recorded on 04/09/25.
Levels Of Support And Resistance For VRDN Stock
The 24-hour chart illustrates a support level at 32.05, which if violated will result in even more drops to 31.79. On the upside, there is a resistance level at 32.81. A further resistance level may holdings at 33.31.
How much short interest is there in Viridian Therapeutics Inc?
A steep rise in short interest was recorded in Viridian Therapeutics Inc stocks on 2025-11-28, dropping by -0.59 million shares to a total of 9.17 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 9.76 million shares. There was a decline of -6.42%, which implies that there is a negative sentiment for the stock.
